Search

Displaying results 9481 - 9490 of 10000 in total
  1. Drug

    Abrilumab

    go.drugbank.com/drugs/DB15076
    Investigational

    Abrilumab is under investigation in clinical trial NCT01290042 (Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.).

  2. Drug

    Acebilustat

    go.drugbank.com/drugs/DB15385
    Investigational

    Acebilustat is under investigation in clinical trial NCT01748838 (Phase 1 Study Assessing the Safety and Tolerability of CTX-4430).

  3. Drug

    Nifekalant

    go.drugbank.com/drugs/DB16008
    Investigational

    Nifekalant is under investigation in clinical trial NCT03855826 (Evaluation of the Efficacy and Safety of Nifekalant Hydrochloride (NIF) Injection).

  4. Drug

    Coprelotamab

    go.drugbank.com/drugs/DB16380
    Investigational

    Coprelotamab is under investigation in clinical trial NCT04170595 (Clinical Study of Recombinant Anti-her2 Humanized Monoclonal Antibody for Injection).

  5. Drug

    Toralizumab

    go.drugbank.com/drugs/DB16384
    Investigational

    Toralizumab is under investigation in clinical trial NCT03605927 (CD40-L Blockade for Prevention of Acute Graft-versus-host Disease).

  6. Drug

    Dasiprotimut-T

    go.drugbank.com/drugs/DB17287
    Experimental

    [A254701] It has been investigated in clinical trials.

  7. Drug

    S64315

    go.drugbank.com/drugs/DB17559
    Investigational

    S64315 (MIK665) is an inhibitor of induced myeloid leukemia cell differentiation protein Myeloid cell leukemia 1 (Mcl-1).[A257311]

  8. Drug

    Rivabazumab pegol

    go.drugbank.com/drugs/DB17788
    Investigational

    Rivabazumab pegol is being investigated as a treatment of Pseudomonas aeruginosa lung infections in patients with cystic fibrosis.[A259457]

    Synonyms: KB001-A (AN ANTI-PCRV PEGYLATED MONOCLONAL ANTIBODY FRAGMENT TO THE TYPE III SECRETION SYSTEM OF PSEUDOMONAS AERUGINOSA)
  9. Drug

    IMT504

    go.drugbank.com/drugs/DB17792
    Investigational

    IMT504, a non-CpG 24-mer oligodeoxynucleotide, is an immunomodulatory oligonucleotide currently being investigated as a rabies vaccine.[A259467]

  10. Drug

    MaaT013

    go.drugbank.com/drugs/DB18648
    Investigational

    MaaT013 is an allogeneic fecal microbiota therapy. It is being investigated for the treatment of Graft-Versus-Host Disease.